FDA Approves Prostate Cancer Drug from OHC Clinical Trial Participation
OHC participated in the clinical trial titled, “A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy.”
This clinical trial studied the clinical benefit of this study drug (when compared to a placebo). Additionally the study looked at the safety of this study drug and the quality of life for the patients who participated in the trial.
The study drug used in this trial was approved for prescription use by the Food and Drug Administration in 2011. Zytiga® (abiraterone acetate) is a treatment for prostate cancer in combination with prednisone for cancers that have spread to different parts of the body and is available by prescription.
For more information, visit Zytiga.